#fabry-disease

icon subthematics
Imaging of Arthritis and Metabolic Bone Disease E-Book
Category

Ebooks

Imaging of Arthritis and Metabolic Bone Disease E-Book

Barbara N. W. Weissman

Imaging of Arthritis and Metabolic Bone Disease E-Book Alternate Text
Category

Ebooks

Medecine

Imaging of Arthritis and Metabolic Bone Disease E-Book

Barbara N. W. Weissman

Book

1679 pages

Flag

English

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)
Category

Documents

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)

Ramaswami Uma, Stull, Parini Rossella, Pintos-Morell Guillem, Whybra Catharina, Kalkum Gisela, Rohrbach Marianne, Raluy-Callado Mireia, Beck Michael, Chen Wen-Hung, Wiklund Ingela, On

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ) Alternate Text
Category

Documents

Savoirs

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)

Ramaswami Uma, Stull, Parini Rossella, Pintos-Morell Guillem, Whybra Catharina, Kalkum Gisela, Rohrbach Marianne, Raluy-Callado Mireia, Beck Michael, Chen Wen-Hung, Wiklund Ingela, On

Book

9 pages

Flag

English

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
Category

Documents

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

Giugliani Roberto, Mehta Atul, Nicholls Kathy, Barisoni Laura, Jennette, Bragat Alexander, Castelli Jeff, Sitaraman Sheela, Lockhart, Germain, Hughes, Boudes

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies Alternate Text
Category

Documents

Savoirs

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

Giugliani Roberto, Mehta Atul, Nicholls Kathy, Barisoni Laura, Jennette, Bragat Alexander, Castelli Jeff, Sitaraman Sheela, Lockhart, Germain, Hughes, Boudes

Book

11 pages

Flag

English

  • 1
Alternate Text